• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

NLA 2025: Emerging Therapies Target Remnant Cholesterol to Address Residual Cardiovascular Risk

by MM360 Staff | Jun 1, 2025 | Myeloma News

Source: Pharmacy Times articles Børge G. Nordestgaard, MD, DMSc, discussed the role of remnant cholesterol as an independent risk factor for atherosclerotic cardiovascular disease and the emerging therapies that may help manage residual cardiovascular risk beyond...

NLA 2025: Practical Strategies for Identifying the Right Patient for Incretin Therapy

by MM360 Staff | Jun 1, 2025 | Myeloma News

Source: Pharmacy Times articles Incretin-based therapies, including GLP-1 and dual GLP-1/GIP receptor agonists, are transforming the management of type 2 diabetes, obesity, and cardiovascular risk. Read More

NLA 2025: Understanding the Impact of Omega-3 Fatty Acids on LDL Cholesterol

by MM360 Staff | Jun 1, 2025 | Myeloma News

Source: Pharmacy Times articles Frank Qian, MD, MPH, discusses clinical considerations for omega-3 fatty acid therapy, such as the patient populations who may benefit most and important safety concerns. Read More

Harnessing the Tumor Microenvironment for Enhanced Cancer Treatment

by MM360 Staff | Jun 1, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

NLA 2025: Exploring the Evidence Behind Omega-3 Fatty Acids for Cardiovascular Risk

by MM360 Staff | Jun 1, 2025 | Myeloma News

Source: Pharmacy Times articles Frank Qian, MD, MPH, discusses the clinical indications, dosing strategies, and cardiovascular outcomes data for prescription omega-3 fatty acids, including the ongoing debate about EPA vs EPA-DHA formulations and the implications of...

From Resistance to Response: The Microbiome’s Role in Optimizing Cancer Therapy

by MM360 Staff | May 31, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More
« Older Entries
Next Entries »

Recent Content

  • Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis
  • Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
  • Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
  • (no title)
  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • (no title)
  • Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
  • (no title)
  • Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT